•
Jun 30, 2023

OrthoPediatrics Q2 2023 Earnings Report

Achieved record quarterly revenue driven by strong commercial and operational performance.

Key Takeaways

OrthoPediatrics Corp. reported a strong second quarter in 2023, achieving record revenue of $39.6 million, a 20% increase compared to the same period last year. The company experienced growth across all revenue segments and geographies, driven by new product development, set consignments, and surgeon training.

Helped over 21,000 children in the second quarter of 2023, bringing the total to over 670,000 since inception.

Generated total revenue of $39.6 million for the second quarter of 2023, up 20% from second quarter 2022; domestic revenue increased 19% and international revenue increased 25% in the quarter.

Grew Trauma & Deformity revenue 22%, Scoliosis revenue 16%; Sports Medicine/Other revenue 23%, worldwide in the second quarter of 2023 compared to the second quarter of 2022.

Consigned $9.2 million of sets in the second quarter of 2023 compared to $3.4 million in the second quarter of 2022, and $3.0 million in the first quarter of 2023.

Total Revenue
$39.6M
Previous year: $32.9M
+20.1%
EPS
-$0.19
Previous year: -$0.17
+11.8%
Gross Profit Margin
76%
Previous year: 75.9%
+0.1%
Gross Profit
$30M
Previous year: $25M
+20.1%
Cash and Equivalents
$9.71M
Previous year: $37.2M
-73.9%
Free Cash Flow
-$10M
Previous year: -$13.4M
-25.6%
Total Assets
$435M
Previous year: $331M
+31.4%

OrthoPediatrics

OrthoPediatrics

OrthoPediatrics Revenue by Segment

OrthoPediatrics Revenue by Geographic Location

Forward Guidance

The Company reiterated its revenue guidance to be in the range of $148.0 million to $151.0 million for the full year 2023, representing growth of 21% to 23% over 2022 revenue. The Company reiterated its expectations for annual set deployments of approximately $25.0 million and $3.0 million to $4.0 million of adjusted EBITDA for the full year of 2023.

Revenue & Expenses

Visualization of income flow from segment revenue to net income